Novo Lowered Inflammation; Phase 3 Still Failed to Protect the Heart
Novo built ZEUS around a clear scientific hypothesis: reducing inflammation should lower cardiovascular risk. Earlier Phase 2 data supported that idea because ziltivekimab produced substantial reductions in high-sensitivity C-reactive protein, or hsCRP. However, ZEUS reported a hazard ratio of 0.99 for major adverse cardiovascular events, which meant the treatment performed almost identically to placebo. Therefore, the trial confirmed biological activity without proving meaningful clinical benefit.
Why a Strong hsCRP Drop Failed to Prevent Heart Attack or Stroke
A pharmacodynamic response shows that a drug reaches and affects its intended pathway. However, patients and regulators need evidence that the same effect improves health outcomes. ZEUS exposed that gap. Inflammation contributes to cardiovascular disease, but it interacts with many other biological and clinical factors. As a result, one biomarker may reflect pathway activity without fully predicting heart attack, stroke or cardiovascular death.
The failure does not make hsCRP useless. Instead, it shows why developers should not treat biomarker movement as a substitute for outcome evidence. Phase 2 RESCUE data showed dose-dependent hsCRP reductions, yet the larger ZEUS trial found no corresponding reduction in cardiovascular events.
Ziltivekimab Missed Its Goal; Serious Infections Deepen the Risk
ZEUS also recorded more serious infections among patients who received ziltivekimab, although all-cause mortality remained similar between the treatment and placebo groups. Consequently, the benefit–risk discussion became harder.
A therapy can justify additional safety risk when it delivers a clear clinical benefit. In this case, however, ziltivekimab added no measurable MACE reduction in the primary analysis. Regulatory, medical and pharmacovigilance teams must now determine whether another patient population could gain enough benefit to offset the immunological risks associated with IL-6 inhibition.
ZEUS Failed; Now HERMES and ARTEMIS Face a Tougher Test
Novo continues to study ziltivekimab in HERMES, which targets heart failure, and ARTEMIS, which focuses on patients after an acute heart attack. Those trials ask different clinical questions, so ZEUS does not automatically determine their outcomes.
Nevertheless, the failure weakens confidence in the broader mechanism and raises the evidence threshold for both programs. R&D leaders should now revisit assumptions about patient selection, endpoint sensitivity, treatment timing and the role of inflammation across each cardiovascular population. Results from the two remaining programs are expected in 2027.
What Novo’s Phase 3 Failure Warns R&D Leaders About
ZEUS offers a clear warning for drug-development portfolios: strong target engagement cannot replace clinical validation. Teams should challenge surrogate assumptions early, test alternative biological explanations and define evidence-based decision points before making costly Phase 3 investments.
Moreover, development leaders should evaluate biomarkers alongside patient outcomes, safety signals and external scientific evidence. One promising measure should never dominate the entire development story when the mechanism, disease pathway and clinical outcome remain uncertain.
Zamann Pharma’s Quality Management System service helps pharmaceutical teams strengthen risk management, quality-focused project governance and evidence-based decision processes across complex programs. Explore the service to build a more structured quality framework before uncertain clinical signals become expensive late-stage decisions.
Source: Biospace.Com